Targeted contrast agent for imaging-guided surgery for extensive cancer treatments
Content of research:
By injecting a contrast agent and illuminating with near-infrared light, cancer cells will show a fluorescent reaction, help to clearly distinguish normal cells and cancer cells, facilitate surgery, and remove tumor clearly. The tumors are unable to be completely removed during surgery in about 1/3 breast cancer patients in USA, the patients have to go in and out of the hospital several times. This is a problem that is not only expensive, but also makes the patient weak, frustrated, and has to undergo multiple surgery. The "Phospho-CSE1L antibody-fluorescent probe" is useful for developing more effective "Targeted
Imaging-Guided Surgery" as tumor cells express high Phospho-CSE1L level.
Innovation & Potential Applications:
Compared to traditional Her2-targted imaging agent
- Phospho-CSE1L targted imaging agent expects to target most cancer types.
- Phospho-CSE1L targted imaging agent expects higher sensitivity and specificity.
A fluorescent label attached to a marker (e.g. a monoclonal antibody) that binds specifically and selectively to tumour cells, helping the surgeon 'see' the tumour and metastatic tissue in real time.
Fluorescent markers can be used with a wide range of procedures, including classic ('open') surgery, laparoscopic surgery, and diagnostic procedures such as colonoscopy.
The fluorescent markers are pharmacologically inactive and are safe to use in both healthy volunteers and patients.